<DOC>
	<DOC>NCT00234858</DOC>
	<brief_summary>The primary objective of this study is to determine whether impaired glucose tolerance is improved to a greater degree by Tarka than Hyzaar in subjects with metabolic syndrome</brief_summary>
	<brief_title>Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Trandolapril</mesh_term>
	<criteria>Metabolic syndrome Fasting blood glucose between 100 mg/dL and 125 mg/dL Hypertension One additional criteria, Exclusion 1 Subject has a current diagnosis of Type 1 or Type 2 diabetes mellitus. Subject has a hypersensitivity to ACE inhibitor, ARB, CCB, clonidine, methyldopa, hydralazine, or thiazide diuretic medication.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Metabolic Syndrome</keyword>
	<keyword>Tarka</keyword>
	<keyword>Hyzaar</keyword>
</DOC>